関連する実験動画
Updated: Jun 3, 2026
11:11
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
16.9K
ctDNAは,ネオアジュバント化学放射線療法後の残留疾患を検出し,食道状細胞がんにおける補助療法をガイドします
Zhichao Liu1, Guoqiang Wang2, Yang Yang3
1Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China.
Cell reports. Medicine
|September 6, 2025
まとめ
パーソナライズされた循環腫瘍DNA (ctDNA) 測定は,治療後の食道がんにおける分子残留疾患 (MRD) を効果的に検出します. ctDNAによるMRDの検出は,個別化された補助免疫療法を導き,生存率を向上させるのに役立ちます.
科学分野:
- 腫瘍学
- 分子診断
- ガンゲノミクス
背景:
- 食道状細胞癌 (ESCC) の多式療法後の分子残留疾患 (MRD) の検出における循環中の腫瘍DNA (ctDNA) の役割については,さらなる明確化が必要である.
- MRDの正確な検出は,治療戦略の調整と患者の結果の予測に不可欠です.
研究 の 目的:
- 局所的に高度なESCC後ネオアジュバント化学放射線療法 (nCRT) のMRD検出のためのパーソナライズドおよび固定パネルctDNAアッセイの診断精度を評価する.
- MRDの検出が生存率と補助免疫療法の有効性に対する影響を評価する.
主な方法:
- nCRTと手術を受けた132人の局所的に進行したESCC患者の前向きなコホート.
- 連続血液サンプルに腫瘍情報に基づくパーソナライズドパネルおよび固定パネルctDNAアッセイを適用する.
- ctDNAの結果と病理的完全応答 (pCR) と生存結果の相関
主要な成果:
- パーソナライズされたctDNAアッセイは,固定パネルと比較して,高基準検出率 (99. 2%) と優れたMRD検出率を示しました.
- パーソナライズされたctDNAを臨床方法と統合することで,非pCRの予測に対する感度 (92. 0% - 93. 2%) が著しく改善されました.
- 治療後の検出可能なMRDは生存率の低下と関連しており,補助免疫療法はMRD陽性非pCR患者にとって有益であった.
結論:
- パーソナライズされたctDNAアッセイは,固定パネルを上回る,ESCCにおけるMRD検出の効果的なツールです.
- ctDNAによるMRD評価は,臓器保存戦略と個別化された補助免疫療法に関する決定を導くことができます.
- MRDの状態は,ESCCにおける治療選択と患者の生存に影響を与える重要な予後要因です.
関連する概念動画
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...